Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma.
Twelve patients with malignant pleural mesothelioma were subjected to mitomycin C (MMC) and vindesine (VDS) chemotherapy (MMC 10 mg/m2, i.v., d 1; VDS, 3 mg/m2, i.v., d 1-8, every 4 weeks). No objective response was obtained; 3 (25%) patients had stable disease and 9 (75%) progression of disease. We conclude that MMC plus VDS is an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma.
Gridelli
C
C
Cattedra di Oncologia Medica, II Facoltà di Medicina, Università degli Studi di Napoli.
Pepe
R
R
Airoma
G
G
Incoronato
P
P
Rossi
A
A
Palazzolo
G
G
Bianco
A R
AR
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy*; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D010997:Pleural Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D014751:Vindesine / Q000008:administration & dosage
D016685:Mitomycin; D014751:Vindesine